New saliva test aims to reduce IVF side effects and improve pregnancy rates
A simple saliva test can help improve the chances of IVF, according to a new study by Swedish researchers.The findings, published in peer-reviewed Frontiers in Endocrinology, has found that a genetic test could reduce harmful side effects for women undergoing fertility procedures.Led by Yvonne Lundberg Giwercman from Lund University, the research highlights how personalised hormone therapy, based on a woman's genetic makeup, can lead to more successful pregnancies.advertisement
About 15% of couples of reproductive age struggle with infertility. A growing number of people are postponing parenthood, leading to a sharp increase in assisted reproduction methods like IVF.However, IVF treatments come with challenges. The procedure involves hormone therapy to stimulate egg production, but nearly 75% of IVF attempts fail.Up to 20% of women experience side effects, some requiring emergency care.'A major issue is that doctors currently have to guess which hormone treatment is best for each woman,' said Ida Hjelmr, the study's first author and a laboratory researcher at Lund University.To find a solution, the team analysed the genes of 1,466 women undergoing IVF.They discovered that women with a specific version of the FSH receptor gene responded better to biological hormones, while others did better with synthetic hormones.advertisementBy matching treatment to genetic type, success rates improved significantly.'We saw a 38% increase in births among women who received hormone therapy that matched their gene variation. That's 110 more babies for every 1,000 women treated,' said Giwercman.To make this process faster and more accessible, the team developed a simple oral swab test that shows the ideal hormone treatment within an hour, visible as a pink or yellow result.The test is expected to be available by early 2026, said Giwercman, who is also the CEO of the company that developed the oral swab test.The researchers have applied for a patent and launched a company, Dx4Life AB, to bring the product to market.They hope the test will lead to more successful IVF outcomes while reducing health risks and healthcare costs.Must Watch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Neeri's giant leap with Global South Network for eco sustainability
Nagpur: The CSIR-National Environmental Engineering Research Institute (CSIR-NEERI) is set to establish a Global South Network to collaborate with institutes across Asia, Africa, Latin America, and Middle East on environmental sustainability. Tired of too many ads? go ad free now A key focus of this initiative is to address critical challenges affecting these regions. In an exclusive interview with TOI on Wednesday, CSIR-NEERI director Dr S Venkata Mohan, an Abdul Kalam Technology Innovation National Fellow, emphasized the network's goal of tackling region-specific environmental issues. "The Global South faces unique challenges, and this platform will amplify our voice to address them collaboratively," he said. The network aims to create a charter, facilitating annual engagements across member countries to develop tailored solutions. "India represents a significant population, and our contributions will carry substantial weight globally," Dr Venkata Mohan added. NEERI also hosts a regional centre for the Stockholm Convention on Persistent Organic Pollutants (POPs), in partnership with the ministry of environment, forest and climate change (MoEFCC). The Stockholm Convention targets chemicals that persist in the environment, spread globally, and accumulate in fatty tissues, posing risks to human health and ecosystems. "We are developing methods to monitor and phase out particulate organic carbon (POC) and other POPs," Dr Venkata Mohan said, highlighting NEERI's role as a recognized regional centre. The Global South Network, an independent initiative, will strengthen NEERI's leadership in environmental research, fostering sustainable development across member nations. Tired of too many ads? go ad free now Also, CSIR-NEERI is in discussion to establish a Centre of Excellence (CoE) in collaboration with IVL Swedish Environmental Research Institute to advance water and wastewater treatment and energy recovery technologies. "A recent Sweden delegation formalized to drive Indo-Swedish sustainability goals," he said. The CoE, to be established at NEERI's Nagpur campus, will serve as a hub for innovative water management solutions, aligning with global circular economy practices. Last year, the Swedish Innovation Agency Vinnova commissioned IVL Swedish Environmental Research Institute to conduct a pre-feasibility study for establishing a Sweden-India Centre of Excellence (CoE) for Sustainable Cities. The study was led by Rupali Deshmukh (Karangale), a native of Nagpur now based in Sweden, who serves as Country Manager for India and CEO of IVL India. IVL has now been tasked with hammering out a detailed feasibility study focusing on water, wastewater, sludge, and energy.
Time of India
2 days ago
- Time of India
Parkinson's disease four times more likely among people with autism, study suggests
New Delhi: People with autism could be four times more likely to develop Parkinson's disease later in life, according to a study among Swedish population. Autism is a neuro-developmental disorder affecting thought processes and social behaviour. It is diagnosed in early childhood, while Parkinson's disease is ageing-related neuro-degeneration, in which one experiences tremors in limbs and affected movement. "This indicates that there can be shared biological drivers behind ASD ( autism spectrum disorder ) and Parkinson's disease," first author Weiyao Yin, a researcher at the department of medical epidemiology and biostatistics, Karolinska Institutet, Sweden, said. The study, published in The Journal of the American Medical Association (JAMA) Neurology, analysed data from more than 22 lakh people born in the country between 1974 and 1999, who were followed from the age of 20 up to the end of 2022. Findings "suggest a potential shared etiology between neuro-developmental disorders and PD (Parkinson's disease), warranting increased awareness of long-term neurological conditions in individuals with ASD," the authors wrote. Yin said, "One hypothesis is that the brain's dopamine system is affected in both cases, since the neurotransmitter (brain chemical) dopamine plays an important part in social behaviour and motion control." While there is considerable evidence that dopamine production is affected in Parkinson's disease, the role of dopamine in autism is not yet clear, even though studies have shown that the brain chemical is involved, the researchers said. The researchers also took into account the fact that people diagnosed with autism are commonly prescribed anti-depressants and anti-psychotic drugs, which can cause Parkinson's-like symptoms. The link between autism and Parkinson's disease became less pronounced, "but the risk was still double", the researchers said. "The healthcare services need to keep people with ASD -- a vulnerable group with high co-morbidity and a high use of psychotropics -- under long-term observation," last author Sven Sandin, a statistician and epidemiologist at the department of medical epidemiology and biostatistics, Karolinska Institutet, said. "At the same time, it's important to remember that a Parkinson's diagnosis before the age of 50 is very rare, including for people with autism," Sandin said. The researchers pointed out that they only analysed early-onset Parkinson's disease before the age of 50 and that the average age of participants by the end of the study was 34. The incidence of Parkinson's disease was therefore very low -- 24 cases among 51,954 people with autism (0.05 per cent), and 438 among 22,26,611 people without autism (0.02 per cent). Future studies will need to examine if the elevated risk persists into older age, the team said. Global estimate of autism prevalence is one per cent, while in India, the estimate is 1.5 per cent, according to a 2023 study published in the Indian Journal of Pediatrics.
Hans India
6 days ago
- Hans India
Study shows impact of weight loss drugs on nerve cells in brain
New Delhi: Swedish researchers have tracked how nerve cells get activated by weight loss drugs such as semaglutide and how it affects the brain. Semaglutide belongs to a group of drugs called GLP-1R agonists and has been shown to effectively reduce food intake and body weight. The drug is already well established as part of the treatment for obesity and type 2 diabetes but can cause side effects such as nausea and muscle loss. In the study, researchers at the Sahlgrenska Academy at the University of Gothenburg showed that it is possible to distinguish the nerve cells in the brain that control the beneficial effects --such as reduced food intake and fat loss -- from those that contribute to side effects. To investigate how semaglutide affects the brain, the researchers worked with mice. They tracked which nerve cells were activated by the drug and were then able to stimulate these cells—without administering the drug itself. The results, published in the journal Cell Metabolism, revealed that the mice ate less and lost weight, just as they did when treated with semaglutide. When these nerve cells were killed, the drug's effect on appetite and fat loss instead decreased significantly. However, side effects such as nausea and muscle loss remained. "This suggests that these nerve cells control the beneficial effects of semaglutide. We have therefore identified a specific group of nerve cells that is necessary for the effects that semaglutide has on weight and appetite, but which does not appear to contribute to any significant extent to side effects such as nausea. "If we can target the treatment there, we may be able to maintain the positive effects while reducing side effects," says Júlia Teixidor-Deulofeu, first author of the study and Ph.D. student at Sahlgrenska Academy at the University of Gothenburg. The identified nerve cells are located in an area of the brain called the dorsal vagal complex. The team noted that the finding is not only an early step toward potentially improved treatment, but it also provides new knowledge about how semaglutide works in the brain. The study also provides deeper insight into how the brain stem regulates our energy balance.
